Teva Pharmaceutical Industries Ltd. First Quarter 2022 Results May 3, 2022 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2022 Results Conference Call May 3, 2022 8:00 AM ET Company Participants Ran Meir - Head, IR Kåre Schultz - CEO Eli Kalif - CFO Sven Dethlefs - Head, North America Commercial Conference Call Participants Balaji Prasad - Barclays David Amsellem - Piper Sandler Eric Masane - Evercore ISI Chris Schott - JPMorgan Elliot Wilbur - Raymond James Ronny Gal - Bernstein Gary Nachman - BMO Capital Markets Bhavin Patel - Bank of America Operator Good day, and thank ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organi ...

| --- | --- | |-------------------------------------|-------| | | | | | | | | | | | | | | | | Teva Pharmaceutical Industries Ltd. | | | Fourth Quarter and Full Year | | | 2021 Results | | | February 9, 2022 | | Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertaintie ...

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Q4 2021 Results Conference Call February 9, 2022 8:00 AM ET Company Participants Ran Meir - SVP, Head IR Kåre Schultz - CEO Eli Kalif - CFO Sven Dethlefs - Head, North America Commercial Conference Call Participants Umer Raffat - Evercore Ronny Gal - Bernstein Elliot Wilbur - Raymond James Navann Ty - Citi Chris Schott - JP Morgan Gary Nachman - BMO Capital Markets Jason Gerberry - Bank of America Operator Good day. And thank you for standing by. And welcome ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE A ...

| --- | --- | |-------------------------------------|-------| | | | | | | | | | | | | | | | | Teva Pharmaceutical Industries Ltd. | | | J.P. Morgan Healthcare Conference | | | Kåre Schultz | | | President & CEO | | | January 11, 2022 | | | | | Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to s ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or or ...

Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorp ...

Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 5 Basel Street, Petach Tikva, ISRAEL 4951033 (Address of principal executive offices) (Zip code) Israel Not Applicable (IRS Employer Iden ...